This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Mucopolysaccharidosis (MPS)

Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)

Sponsored by Shire

About this trial

Last updated 4 years ago

Study ID

SHP-001-801

Status

Terminated

Type

Observational

Phase

N/A

Placebo

No

Accepting

18-75 Years
Up to 7 Years
Male
Male

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 10 years ago

What is this trial about?

Mucopolysaccharidosis (MPS) type II (MPS II; Hunter syndrome) is a rare, X-linked disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S) and occurs almost exclusively in boys, with an incidence of approximately 1.3 per 100,000 live male births.1 Early identification of MPS II is challenging because some initial features, such as chronic runny nose, otitis media, and hernias, are commonly seen in the general population. As a result, even though the signs and symptoms of MPS II typically appear early in childhood, the diagnosis may lag behind by several years. The primary objective of this international multi-center study is to evaluate the positive screening rate of MPS II subjects by screening a high-risk male pediatric population who have had or are scheduled for 1 or more specific ENT surgical procedures (adenoidectomy and/or tonsillectomy and/or tympanostomy) and who have a previously repaired or present evidence of an inguinal and/or umbilical hernia.

What are the participation requirements?

Yes

Inclusion Criteria

Each subject must meet the following criteria to be enrolled in this study: 1. The subject is male. 2. The subject is <7 years of age. 3. The subject has had or is scheduled for ENT surgery for any of the following, alone or in combination: adenoidectomy, tonsillectomy, and tympanostomy. 4. The subject has record of previous surgical repair or presence of inguinal and/or umbilical hernia. 5. The subject's parent(s) or the subject's legally authorized representative(s) has provided written informed consent that has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).

No

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from the study: 1. The subject has a current confirmed diagnosis of any MPS disorder. 2. The subject was born prematurely (defined as born before 37 weeks gestation). 3. The subject has received a blood transfusion within the past 6 weeks. 4. The subject has received a bone marrow transplant.

Clinical Study Report Synopsis

Locations

Location

Status

For more information, view the full study details:

NCT02095015